甲酸乙酯1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代羟基吡啶[2,3-B]吡啶-3-羧酸 | 100491-29-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 甲酸乙酯1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代羟基吡啶[2,3-B]吡啶-3-羧酸
• 中文别名: 7-氯-1-(2,4-二氟苯基)-6-氟-4-氧代-1,4-二氢-1,8-萘啶-3-羧酸乙酯；1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代吡啶并[2,3-b]吡啶-3-羧酸乙酯
• 英文名称: ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate
• 英文别名: 7-chloro-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester；ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylate
• CAS: 100491-29-0
• 化学式: C₁₇H₁₀ClF₃N₂O₃
• 分子量: 382.726
• InChiKey: JLSXYCZRMYCIMY-UHFFFAOYSA-N

物化性质

• 熔点：
  212-215 °C
• 沸点：
  502.5±50.0 °C(Predicted)
• 密度：
  1.4752 (estimate)
• 溶解度：
  DMSO（轻微、加热）、甲醇（非常轻微、加热）
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  29339980
• 危险性防范说明：
  P261,P280
• 危险性描述：
  H317
• 储存条件：
  存于阴凉干燥处。

SDS

Name:	Ethyl Material Safety Data Sheet
Synonym:
CAS:	100491-29-0

Section 1 - Chemical Product MSDS Name:Ethyl Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
100491-29-0	Ethyl-1-(2,4-difluorophenyl)-7-Cl-6-F-	99%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 100491-29-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: almost white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 212-215 C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H10ClF3N2O3
Molecular Weight: 382.5298

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acetic anhydride, acid chlorides, carbon dioxide.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 100491-29-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl-1-(2,4-difluorophenyl)-7-Cl-6-F-4-oxohydropyridino[2,3 - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 100491-29-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 100491-29-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 100491-29-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  甲酸乙酯1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代羟基吡啶[2,3-B]吡啶-3-羧酸 在 硫酸 、 potassium nitrate 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 乙醇 、 氯仿 为溶剂， 生成 ethyl 7-chloro-1-(2,4-difluoro-5-nitrophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate
  参考文献：
  名称：

  Pyridonecarboxylic acid derivatives or salts thereof and antibacterial

  摘要：

  该发明提供了以下一般式（1）的吡啶酮羧酸衍生物： 其中R.sup.1是氢原子或羧基保护基，R.sup.2是硝基或取代或未取代的氨基，R.sup.3是卤素原子，R.sup.4和R.sup.5中的每一个，可以相同也可以不同，是氢原子、卤素原子、低烷基基团或低烷氧基团，A是氮原子或--CX.dbd.，其中X是氢原子、卤素原子、低烷基基团或低烷氧基团，Z是卤素原子或饱和环状氨基团，可能带有取代基，或其盐以及包含其的抗菌剂。

  公开号：

  US05910498A1
• 作为产物：
  描述：

  2,6-二氯-5-氟吡啶-3-羧酸乙酯 在 盐酸 、 正丁基锂 、 氯化亚砜 、 2,2'-联喹啉 、 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 水 、 乙酸酐 为溶剂， 反应 33.0h， 生成 甲酸乙酯1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代羟基吡啶[2,3-B]吡啶-3-羧酸
  参考文献：
  名称：

  ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS

  摘要：

  本文披露了具有抗病毒和抗菌活性的胍和双胍衍生物。还披露了含有这些化合物作为活性成分的药物组合物，以及利用这些化合物的抗病毒和抗菌方法。还披露了使用胍和双胍衍生物治疗感染的方法。

  公开号：

  US20140073631A1
• 作为试剂：
  描述：

  (1S,5R)-3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane 在 Pd on carbon 氢气 、 三乙胺 、 苯甲醛 、 甲酸乙酯1-(2,4-二氟苯基)-7-氯-6-氟-4-氧代羟基吡啶[2,3-B]吡啶-3-羧酸 作用下， 以 水 、 异丙醇 为溶剂， 50.0 ℃ 、344.75 kPa 条件下， 反应 24.0h， 以75.5%的产率得到ethyl (1α,5α,6α)-7-chloro-(6-benzylidenylamino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Process for preparing trovafloxacin acid salts

  摘要：

  Trovafloxacin 酸盐是通过使用包括但不限于甲磺酸、乙磺酸、苯磺酸、硝酸、硫酸、磷酸、盐酸、氢溴酸、酒石酸、柠檬酸、醋酸和马来酸的矿物酸对亚胺中间体进行水解而制备的。Trovafloxacin 酸盐作为抗生素药物是有用的。

  公开号：

  US06359137B1

文献信息

• 7-isoindolinyl-quinolone-carboxylic acid derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US05464796A1

  公开（公告）日：1995-11-07

  The invention relates to new quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in the 7-position by a partly hydrogenated isoindolinyl ring, processes for their preparation and antibacterial agents and feed additives containing these compounds.

  本发明涉及新的7-位部分氢化的异喹啉基取代的喹诺酮和萘啶酮羧酸衍生物，它们的制备方法，以及含有这些化合物的抗菌剂和饲料添加剂。
• Azabicyclo quinolone and naphthyridinone carboxylic acids
  申请人：Pfizer Inc

  公开号：US05164402A1

  公开（公告）日：1992-11-17

  Quinolone carboxylic acids 7-substituted by azabicyclo groups have antibacterial activity.

  喹诺酮羧酸7位被氮杂双环基团取代的化合物具有抗菌活性。
• Synthesis of trovafloxacin using various (1α,5α,6α)-3-azabicyclo[3.1.0]hexane derivatives
  作者：Timothy Norris、Tamim F. Braish、Michael Butters、Keith M. DeVries、Joel M. Hawkins、Stephen S. Massett、Peter R. Rose、Dinos Santafianos、Constantine Sklavounos

  DOI：10.1039/a910340f

  日期：——

  6α)-3-azabicyclo[3.1.0]hexane ring system. The prototype of the industrial synthesis of this ring system and possible mechanistic pathways to exclusive formation of the exo or 6α-nitro derivative 4 are described, which leads to the key 6α-nitro-3-azabicyclo[3.1.0]hexane intermediate 10. The synthesis of 6α-amino-3-azabicyclo[3.1.0]hexane 16 and useful protected exo 6-amino derivatives 15 and 17 follows

  曲伐沙星一本新颖的小说 光谱抗菌，含有不寻常的（1α，5α，6α）-3-氮杂双环[3.1.0]己烷环系统。描述了该环系统的工业合成原型以及排他性地形成exo或6α-硝基衍生物4的可能的机理途径，这导致了关键的6α-硝基-3-氮杂双环[3.1.0]己烷中间体10。6α-氨基-3-氮杂双环[3.1.0]己烷16和有用的受保护的exo 6-氨基衍生物15和17的合成从10开始。这些可以与7-氯萘啶酮18结合，得到受保护的曲伐沙星化合物20–22产量高。曲伐沙星21的乙酯也可以从偶联物19的产物中获得，该偶联物衍生自18和外6-硝基-3-氮杂双环[3.1.0]己烷化合物12。用20到22的保护基去除甲磺酸 产量 甲磺酸曲伐沙星碱处理可从其中释放曲伐沙星两性离子1。两性离子 1也可以直接由16甲苯磺酸盐和萘啶酮-2-羧酸26制备。
• Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids
  作者：Terry Rosen、Daniel T. W. Chu、Isabella M. Lico、Prabhavathi B. Fernandes、Kennan Marsh、Linus Shen、Valerie G. Cepa、Andre G. Pernet

  DOI：10.1021/jm00403a020

  日期：1988.8

  The quinolonecarboxylic acids constitute a class of extremely potent and orally active broad-spectrum antibacterial agents. These compounds have been shown to inhibit DNA gyrase, a key enzyme in bacterial DNA replication. The 7-(3-aminopyrrolidinyl)quinolone A-60969 (1) is a particularly potent member of this class and is currently undergoing clinical evaluation. We have studied a series of enantiomerically

  喹诺酮羧酸构成一类非常有效且具有口服活性的广谱抗菌剂。这些化合物已显示出抑制DNA回旋酶的作用，而DNA回旋酶是细菌DNA复制中的关键酶。7-（3-氨基吡咯烷基）喹诺酮A-60969（1）是此类中特别有效的成员，目前正在临床评估中。我们已经研究了一系列对映体均质的（4S）-7-（4-氨基-2-取代的吡咯烷基）喹诺酮类药物，以利用吡咯烷部分的2位改善此类药物的溶解度和药代动力学性质化合物，同时仍保持有效的抗菌活性。我们已经发现，在吡咯烷环的2-位上的绝对立体化学对于维持这种活性至关重要。在本文中，我们报告了该系列化合物的不对称合成以及体外和体内结构-活性关系的完整详细信息，以及与结构修饰相关的理化特性，例如水溶性和logP。我们还讨论了这些化合物中的几种在小鼠中的药代动力学特性，以及在本研究中在狗中具有最佳药物总体特性的59的药代动力学。
• Syntheses and antibacterial activity of novel 6-fluoro-7-(<i>gem</i>-disubstituted piperazin-1-yl)-quinolines
  作者：Daniel T. W. Chu、Akiyo K. Claiborne、Jacob J. Clement、Jacob J. Plattner

  DOI：10.1139/v92-171

  日期：1992.5.1

  A series of quinoline and naphthyridine antibacterial agents possessing an acyclic or cyclic gem-disubstituted piperazine substituent at the C-7 position have been prepared and evaluated in vitro and in vivo for antibacterial activity against a variety of Gram-positive and Gram-negative organisms. They are, however, not as active as quinolones or naphthyridines with a monosubstituted piperazine substituent at C-7. The chemical synthesis of these derivatives is also described.

  已经制备并评估了一系列含有在C-7位置带有非环状或环状的双取代哌嗪基团的喹啉和萘啶类抗菌剂，用于对多种革兰氏阳性菌和革兰氏阴性菌的体外和体内抗菌活性的研究。然而，它们并不像在C-7位置带有单取代哌嗪基团的喹诺酮或萘啶那样有效。这些衍生物的化学合成也被描述了。